Palisade Bio director buys 50,000 company shares

Palisade Bio director Robert Baltera Jr. reported open-market purchases of a total of 50,000 shares of common stock.

Rhea-AI Filing Summary

Palisade Bio director Robert Baltera Jr. reported open-market purchases of a total of 50,000 shares of common stock. He bought 20,000 shares on July 6, 2026 at a weighted average price of $2.052 per share and 30,000 shares on July 7, 2026 at a weighted average price of $2.0348 per share. The filing notes the trades were executed in multiple transactions within price ranges of $2.04–$2.068 and $2.00–$2.07. Following these purchases, Baltera directly owns 416,904 shares of Palisade Bio common stock.

Insider Trade Summary

Net Buyer: 50,000 shares

Net Buy 2 txns

Insider Baltera Robert Jr.

Role Director

Bought 50,000 shs ($102K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	30,000	$2.0348	$61K
Purchase	Common Stock	20,000	$2.052	$41K

Holdings After Transaction: Common Stock — 416,904 shares (Direct)

Footnotes (2)

1. F1. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.04 to $2.068. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.00 to $2.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Total shares purchased: 50,000 shares July 6, 2026 purchase: 20,000 shares at $2.052 July 7, 2026 purchase: 30,000 shares at $2.0348 +3 more

6 metrics

Total shares purchased 50,000 shares Open-market purchases reported in Form 4

July 6, 2026 purchase 20,000 shares at $2.052 Weighted average price on 2026-07-06

July 7, 2026 purchase 30,000 shares at $2.0348 Weighted average price on 2026-07-07

Post-transaction holdings 416,904 shares Common stock directly owned after July 7, 2026 trade

Price range July 6, 2026 $2.04–$2.068 Multiple executions; weighted average $2.052

Price range July 7, 2026 $2.00–$2.07 Multiple executions; weighted average $2.0348

Key Terms

open-market purchase, weighted average price, Form 4, Common Stock

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for each common stock trade"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): { "issuerName": "PALISADE BIO, INC.""

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

""security_title": "Common Stock" for both reported transactions"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Palisade Bio (PALI) report in this Form 4?

Palisade Bio reported that director Robert Baltera Jr. bought 50,000 common shares in open-market transactions. The purchases occurred on July 6 and 7, 2026, and increased his direct ownership to 416,904 shares of Palisade Bio stock.

How many Palisade Bio (PALI) shares did the director purchase and at what prices?

The director purchased 20,000 shares at a weighted average price of $2.052 and 30,000 shares at $2.0348. Footnotes state the trades were split across multiple executions within ranges of $2.00–$2.07 per share.

What is Robert Baltera Jr.’s total Palisade Bio (PALI) holding after these trades?

After the reported open-market purchases, Robert Baltera Jr. directly owns 416,904 shares of Palisade Bio common stock. This figure, disclosed in the Form 4, reflects his position immediately following the July 7, 2026 transaction.

Were the Palisade Bio (PALI) insider purchases single trades or multiple executions?

The insider purchases were executed as multiple trades. The filing explains that reported prices are weighted averages, with individual executions occurring within price ranges of $2.04–$2.068 and $2.00–$2.07 per share for the two trading days.

Is the Palisade Bio (PALI) director’s transaction classified as a buy or sell?

The transactions are classified as open-market purchases, meaning they are buys. The Form 4 coding and summary show two purchase transactions (code P), totaling 50,000 shares, with no reported sales or other dispositions in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 06:56 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baltera Robert Jr.

(Last) (First) (Middle)

C/O PALISADE BIO, INC.

4600 SOUTH SYRACUSE STREET, SUITE 900

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		P		20,000	A	$2.052(1)	386,904	D
Common Stock	07/07/2026		P		30,000	A	$2.0348(2)	416,904	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.04 to $2.068. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.00 to $2.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Ryker Willie, Attorney-in-Fact for Robert Baltera Jr.	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)